Trifecta Capital Advisors LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 86.4% within the second quarter, based on its most up-to-date Kind 13F submitting with the SEC. The fund owned 2,607 shares of the corporate’s inventory after promoting 16,624 shares in the course of the interval. Trifecta Capital Advisors LLC’s holdings in Johnson & Johnson have been price $381,000 as of its most up-to-date SEC submitting.
Different hedge funds have additionally added to or diminished their stakes within the firm. Residents & Northern Corp grew its place in Johnson & Johnson by 3.5% in the course of the 2nd quarter. Residents & Northern Corp now owns 1,884 shares of the corporate’s inventory price $275,000 after buying a further 63 shares over the last quarter. Carolinas Wealth Consulting LLC grew its holdings in shares of Johnson & Johnson by 0.4% within the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the corporate’s inventory price $2,643,000 after buying a further 64 shares over the last quarter. Epic Belief Funding Advisors LLC raised its holdings in Johnson & Johnson by 3.6% in the course of the 2nd quarter. Epic Belief Funding Advisors LLC now owns 1,831 shares of the corporate’s inventory valued at $268,000 after shopping for a further 64 shares over the last quarter. Verity Asset Administration Inc. boosted its place in Johnson & Johnson by 2.0% in the course of the 4th quarter. Verity Asset Administration Inc. now owns 3,268 shares of the corporate’s inventory valued at $512,000 after shopping for a further 65 shares in the course of the interval. Lastly, Clothes shop Monetary LLC grew its holdings in Johnson & Johnson by 0.4% within the 2nd quarter. Clothes shop Monetary LLC now owns 16,632 shares of the corporate’s inventory price $2,431,000 after buying a further 65 shares over the last quarter. Institutional traders personal 69.55% of the corporate’s inventory.
Insider Exercise at Johnson & Johnson
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of the corporate’s inventory in a transaction dated Friday, August thirtieth. The shares have been bought at a mean value of $165.06, for a complete transaction of $930,113.10. Following the transaction, the vice chairman now owns 18,973 shares within the firm, valued at roughly $3,131,683.38. The transaction was disclosed in a doc filed with the Securities & Alternate Fee, which is accessible by means of this hyperlink. 0.16% of the inventory is at present owned by insiders.
Johnson & Johnson Inventory Efficiency
Shares of Johnson & Johnson inventory opened at $164.64 on Friday. Johnson & Johnson has a 1 yr low of $143.13 and a 1 yr excessive of $168.85. The agency’s 50-day shifting common is $159.17 and its 200 day shifting common is $154.00. The inventory has a market cap of $396.24 billion, a price-to-earnings ratio of 10.26, a PEG ratio of two.71 and a beta of 0.53. The corporate has a debt-to-equity ratio of 0.44, a present ratio of 1.07 and a fast ratio of 0.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final posted its quarterly earnings outcomes on Wednesday, July seventeenth. The corporate reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a web margin of 46.34% and a return on fairness of 36.60%. The agency had income of $22.45 billion for the quarter, in comparison with analysts’ expectations of $22.33 billion. Throughout the identical quarter within the prior yr, the corporate posted $2.80 earnings per share. The enterprise’s income for the quarter was up 4.3% on a year-over-year foundation. Promote-side analysts anticipate that Johnson & Johnson will put up 10.02 EPS for the present fiscal yr.
Johnson & Johnson Dividend Announcement
The agency additionally not too long ago declared a quarterly dividend, which was paid on Tuesday, September tenth. Stockholders of file on Tuesday, August twenty seventh have been paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of three.01%. The ex-dividend date of this dividend was Tuesday, August twenty seventh. Johnson & Johnson’s dividend payout ratio is at present 30.92%.
Analysts Set New Value Targets
A variety of analysts have not too long ago weighed in on JNJ shares. Morgan Stanley elevated their goal value on shares of Johnson & Johnson from $167.00 to $169.00 and gave the inventory an “equal weight” score in a report on Thursday, July 18th. The Goldman Sachs Group reduce their value goal on Johnson & Johnson from $160.00 to $155.00 and set a “impartial” score on the inventory in a analysis report on Friday, July nineteenth. Cantor Fitzgerald reaffirmed an “obese” score and issued a $215.00 value goal on shares of Johnson & Johnson in a analysis observe on Monday. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” score to a “purchase” score in a analysis report on Friday, September sixth. Lastly, TD Securities reduce their goal value on shares of Johnson & Johnson from $195.00 to $185.00 in a analysis observe on Thursday, July 18th. Seven analysts have rated the inventory with a maintain score and 7 have assigned a purchase score to the corporate’s inventory. Based on knowledge from MarketBeat.com, the inventory at present has a mean score of “Reasonable Purchase” and a mean value goal of $173.21.
Verify Out Our Newest Inventory Evaluation on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare subject worldwide. The corporate’s Progressive Medication section presents merchandise for numerous therapeutic areas, equivalent to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, equivalent to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Additional Studying
Wish to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Rankings for Johnson & Johnson Each day – Enter your e mail handle under to obtain a concise each day abstract of the most recent information and analysts’ rankings for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE each day e mail e-newsletter.
